-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
tumor mutation burden
-
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective
By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients with lung cancer has been described extensively by many experts within the IASLC.1,2 There are, however, broad disparities in outcomes for patients with lung cancer…
-
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced NSCLC, with prolonged duration of response and significant 5-year survival rates not seen with combination platinum-based chemotherapy.1-6 CheckMate 012, CheckMate 568, and CheckMate 227 are…
-
2019 IASLC World Conference on Lung Cancer Updates
Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of thoracic oncology patient care, the conference offered attendees from all specialties an opportunity to learn about novel research and hear from the field’s top experts.…
View ILCN Archives
Provider Resources
Popular Articles